- Home
- SILC vs ACHV Comparison
SILC vs ACHV Comparison
Compare SILC & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SILC | ACHV |
|---|---|---|
| Founded | 1987 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.8M | 172.0M |
| IPO Year | 2002 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SILC | ACHV |
|---|---|---|
| Price | $41.34 | $5.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $14.67 |
| AVG Volume (30 Days) | 180.2K | ★ 1.3M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.17 | N/A |
| Revenue Next Year | $12.28 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.34 | $2.00 |
| 52 Week High | $52.58 | $6.15 |
Technical Indicators
Market Signals| Indicator | SILC | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 50.69 | 58.87 |
| Support Level | $40.00 | $4.09 |
| Resistance Level | $50.75 | $5.84 |
| Average True Range (ATR) | 4.20 | 0.42 |
| MACD | -0.99 | -0.03 |
| Stochastic Oscillator | 5.15 | 48.26 |
Price Performance
Historical ComparisonAbout SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.